ClinicalTrials.gg
RecruitingNCT06619002LYSEUpdated Oct 2, 2024

Implementation of Surgical Safety and Intraoperative Metastasis Identification Through Deep Learning: Multicentric Video Collection for Minimally Invasive Sentinel Lymph Node Dissection in Uterine Malignancies

An observational study in Endometrial Cancer, Cervical Cancer and Deep Learning, sponsored by Fondazione Policlinico Universitario Agostino Gemelli IRCCS. Recruiting at 2 sites in Italy. Open to female participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2024-10-02.

Sponsored by Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Observational

How we know

From the registry’s dates

  • Started Sep 2024; still recruiting 2 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
100
Ages
18 Years to 99 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 17 studies in Endometrial Neoplasms by Fondazione Policlinico Universitario Agostino Gemelli IRCCS — 15 open to participants now, 16 under way, none of them phase 3. Endometrial Neoplasms · Fondazione Policlinico Universitario Agostino Gemelli IRCCS.

Planned enrollment
9th of 12
100 · median 160
Started
2024
with 5 others
Observational
12 of 17
11 open now
Primary completion
2026-09
later than 9 of 15 live
Registered
7th of 17
by date

Among the 17 studies in Endometrial Neoplasms by Fondazione Policlinico Universitario Agostino Gemelli IRCCS, this one is the 9th largest by planned enrollment of the 12 observational ones that give a count, is one of 6 that started in 2024, is one of 12 observational ones, reaches primary completion later than 9 of the 15 other live ones, and was the 7th registered.

Endometrial Neoplasms

1,429 studies on the registry are indexed under Endometrial Neoplasms; 470 are open to participants now.

Browse Endometrial Neoplasms studies →

Open to participants now

15 of the 17 studies in Endometrial Neoplasms by Fondazione Policlinico Universitario Agostino Gemelli IRCCS are open now, in 1 country. Recruiting first, the newest first:

9 more — sign in →

By country, each count listing its studies:

All 15 open studies →

Where they have run

Who these studies take

Of the 356 Endometrial Neoplasms studies recruiting now, 266 (75%) set no upper age limit and 54 (15%) stop at 75 or younger; 26 take children under 18; 23 take healthy volunteers.

This study: 18 Years to 99 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Endometrial Neoplasms by Fondazione Policlinico Universitario Agostino Gemelli IRCCS, or all of them as a file.
02

Study summary

The loco-regional metastatic or non-metastatic status of lymph nodes (LN) is critical for the therapeutic management of most cancer patients. Indeed, the presence or absence of lymphatic metastasis is essential for the accurate staging of the disease and strongly influence the prognosis and adjuvant treatment regimens. An important revolution in oncological surgery has been the introduction of the concept of sentinel lymph node (SLN) biopsy to reduce the complications of extensive loco-regional lymphadenectomies. SLN identification through ICG- based near-infrared fluorescence (NIR) cervical injection and its dissection is now recommended by European guidelines to stage uterine malignancies (endometrial and cervical cancers). However, SLN procedures have several limitations. In 11.2% of cases intra- or postoperative complications are reported due to anatomical structures injuries (vessels, nerves and lymphatic channels disruptions). Common mistakes, especially when the learning curve is not completed (at least 40 procedures), include mapping failure (25%) and removal of second/third-level nodes and/or empty nodes packets (8-14%). Additionally the intraoperative accuracy of frozen section is still far to be adequate with only the 65% of SLN metastasis detection.

These limitations are a result of the lack of precision of current SLN localization and analysis as well as of the overall difficulty of visualizing lymph nodes and other critical structures in the retroperitoneum.

Currently, studies on the safety of surgical procedures are based on perioperative clinical information and postoperative reports written by the surgeons themselves. Today, videos guiding minimally invasive surgical interventions allow for objective documentation of the procedure and provide opportunities to explore solutions for enhancing safety in the operating room. With an increasing use of endoscopic systems across different specialties, there is a need for standardization of training, assessment, testing and sign-off as a competent surgeon in order to improve patient safety. In laparoscopic lymph node dissection in endometrial and cervical cancer, a standardize stepwise approach to the procedure is highly recommended, by identifying key anatomic landmarks and structures, in various scenarios, that could prevent vascular, nervous and ureters injuries and enhance the mapping rate. Therefore, quantifying and studying intraoperative events such as the rate of achieving the right space dissections and anatomic structures visualization as a recommended step for safety and proficiency, would enable the examination of how best to implement guideline recommendations and seek new solutions to reduce operative risks. These videos could be utilized to train and validate artificial intelligence (AI) algorithms, with the potential to assist surgeons in the operating room and make the procedures safer. Additionally, the visual information (ICG intensity) could hide data that the AI can analyze and correlate with anatomopathological reports. By the integration of AI tool with laparoscopic/robotic platform it is possible to enhance MIS video streams in real time with surgical phases detection, events recognition, ICG signal intensity, anatomical structure identification and auto-targeting

Read the detailed description

Surgery accounts for approximately two-thirds of all hospital complications. About 75% of these complications occur during surgical interventions, and half of them are considered preventable. Traditionally, studies on surgical safety have relied mainly on perioperative information and written reports from the surgical operators themselves. Nowadays, videos that guide the surgeon during minimally invasive procedures can be easily recorded, providing objective documentation of surgical interventions. Studying surgical videos and quantifying intraoperative events offer a promising new perspective on the causes of adverse events, with the potential to develop solutions for reducing surgical risks and facilitating the implementation of international safety recommendations in surgery .

Furthermore, recent advancements in Artificial Intelligence (AI) have shown great success in image understanding, raising the possibility of developing algorithms for automatic and large-scale analysis of surgical videos. These AI algorithms could also analyze surgical videos in real-time and provide decision support in the operating room.

The assessment of lymph node status is of crucial importance in uterine malignancies (endometrial and cervical cancer). The rate of positive lymph nodes in apparently early stage cancers is far to be low (10% endometrial and cervical 15% ). Indeed, the prognosis and adjuvant treatment regimens are strongly influenced by the presence of nodal involvement. Systematic extensive lymphadenectomies are often performed for staging, diagnosis of skip metastases and to define the radiation field when adjuvant radiotherapy treatments are required. Nevertheless, pelvic and/or para- aortic lymphadenectomy can lead to significant short-term and long-term complications.

What makes the burden of surgical morbidity even more difficult to bear is that in most cases, regardless of the type of pelvic malignancy, the lymph nodes are free from metastasis. This means that the majority of patients undergo an unnecessary, risky, and burdensome procedure that has no proven impact on their survival. To solve this issue in early stage endometrial and cervical cancers, evaluation of the sentinel lymph node (SLN) has acquired a valuable role..The evaluation of the first lymph node or group of lymph nodes draining the initial lesion and therefore the first station to collect neoplastic cells in case of tumor nodal spread allows node-negative patients to be spared from the surgical comorbidities associated with systematic lymphadenectomy. However even if only SLN is removed, the rate of surgical complications is still high. Capozzi et al reported a 11.2% complications rate related to intra- operative injuries of vessels, nerves, and ureters and to post-operative evidence of lymphoceles and lymphedemas due to wrong anatomy dissection and lymphatic channels disruption. It is reported a 25% of SLN mapping failure according to patients and cancer characteristics and variability in the surgical steps. In 2021 Moloney et al and in 2023 Bizzarri et al published a Delphi consensus for SLN surgical steps in endometrial and cervical cancer to improve the clinical outcomes, decrease surgical complications and bias in multicentric prospective trials. To date a learning curve of 40 procedures is demonstrated to be needed for successful bilateral mapping. Furthermore, in some case it is reported the inadvertent failure to harvest nodal tissue in 14% of cases (higher rate in obese patients with endometrial cancer) with empty packets that may lead to overtreatment for patient safety. Sentinel node frozen section analysis tough then is not routinely performed due to its disadvantage in terms of time consumption and not accurate results for micro-metastasis detection (65% of detection accuracy) thereby losing part of the techniques potential.

In laparoscopic cholecystectomy, the critical view of safety (CVS) has been described to reduce the risk of bile duct injury. We aim to adapt concepts of "culture of safety" to laparoscopic SLN node dissection by identifying key anatomic landmarks and structures, in various scenarios, that could prevent intra- operative injuries and enhance the mapping rate by following the standardized surgical steps.

Therefore, quantifying and studying intraoperative events such as the rate of achieving the recommended surgical steps, would enable the examination of how best to implement guideline recommendations and seek new solutions to reduce operative risks. Furthermore, these videos could be utilized to train and validate artificial intelligence (AI) algorithms, with the potential to assist surgeons in the operating room helping in the training to reach faster the learning curve and improve the procedural safety. Infact, recent AI algorithms capable of automatically assessing and documenting the critical view of safety (CVS) with short videos could be utilized to support the implementation of guidelines and make laparoscopic SLN dissection safer.

Analyzing videos of laparoscopic SLN dissection performed at referral centers could help assess the implementation of a stepwise approach to the procedure and the development of a critical view of safety (CVS) along with other guideline recommendations, as well as develop new solutions for safe laparoscopic SLN dissection. The steps to identification and the "Critical view of safety" are fully described in the study. Our project emphasizes the importance of achieving these views of safety before proceeding to the next step of the procedure. The next step involves analysing the intensity of the fluorescent signal and correlating it, as no-one has ever done, with the histological diagnosis of the sentinel lymph node to assess the possibility of correlation between intensity and metastatic nature.

Additionally, AI algorithms for safe laparoscopic SLN dissection could be tested on the collected videos from multiple hospital centers to adequately study the generalizability of these algorithms before clinical translation.

Purposes and objective of the clinical study:

The objective of this study is to establish the rate of critical view of safety (CVS) for safe laparoscopic SLN dissection in a multicentre cohort of surgical videos to reduce complications, the surgical learning curve and correlate ICG intensity with the lymph node metastatic nature

03

Conditions studied

  • Endometrial Cancer
  • Cervical Cancer
  • Deep Learning
  • Artificial Intelligence

Keywords

  • endometrial cancer
  • cervical cancer
  • deep learning
  • computer vision
  • sentinel lymph node
  • artificial intelligence
  • indocyanin green
04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Women undergoing laparoscopic or robotic sentinel lymph node dissection for endometrial or cervical cancer

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Women undergoing MIS sentinel lymph node dissection for endometrial or cervical cancers
  • Availability of video
  • Age >18 years
  • Willingness to participate in the study and to provide

Exclusion criteria

Exclusion Criteria:

  • Previous pelvic radiotherapy treatments
  • Severe endometriosis or other conditions able to alter the pelvic anatomy
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
100 participants (estimated)
Target follow-up
5 Years
Patient registry
Yes

Interventions

  • ProcedureSentinel lymph node sampling

    video analysis

    Also known as: sentinel lymph node detection, sentinel lymph node dissection, sentinel lymph node biopsy

06

What researchers measure

Primary outcomes

  1. Evaluate the rate of achieving critical view of safety (CVS) according to standard agreement recommendations in Laparoscopic SLN dissection procedures performed at centers involved in the study.

    The rate of Critical views of safety achievement will be evaluated in a video-based assessment by experts gyn surgeons and labeled according to the annotation protocol. The inter-rather agreement will be therefore also evaluated

    Time frame: 24 months

Secondary outcomes

  1. Develop an Artificial intelligence tool

    able to reduce perioperative complications ( graded according to Clavien-Dindo scale)

    Time frame: 24 months

  2. Develop an Artificial intelligence tool

    able to reduce the rate of empty packets (expressed in percentage and evaluated with pathology as gold standard)

    Time frame: 24 months

  3. Develop an Artificial intelligence tool

    able to implement the surgical learning curve measured as the rate of mapping failure and of empty packets

    Time frame: 24 months

  4. Develop an Artificial intelligence tool

    able to define the presence of micro and macro-metastasis correlating with ICG fluorescence (evaluated with pathology as a gold standard and measured in percentages)

    Time frame: 24 months

07

Study locations

2 of 2 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2024 (actual). Primary completion is estimated for Sep 2026, 24 months after the start.

Of 130 non-industry observational studies under Endometrial Neoplasms, half reached primary completion within 66 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 206. This study's planned 24 months is below that.

Counting every sponsor, half of 150 studies reached it within 105 months; a quarter within 32 and three quarters within 206.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 24, 2024
First posted
Oct 1, 2024
StartActual
Sep 17, 2024
Primary completionEst.
Sep 30, 2026
CompletionEst.
Sep 30, 2027
Last update
Oct 2, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 2, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06619002
Collaborators
IHU Strasbourg, University Hospital, Strasbourg
Responsible party
Bizzarri Nicolò (Principal Investigator, Fondazione Policlinico Universitario Agostino Gemelli IRCCS) — Principal investigator
First posted
Oct 1, 2024
Start date
Sep 17, 2024
Primary completion
Sep 30, 2026 (estimated)
Completion
Sep 30, 2027 (estimated)
Last update
Oct 2, 2024

Study contacts

Matteo PAVONE, MD
Contact
matteo.pavone@guest.policlinicogemelli.it
00390630151
Matteo PAVONE, MD
principal investigator · Fondazione Policlinico Universitario A. Gemelli, IRCCS, Rome Italy; IHU Strasbourg; IRCAD Strasbourg; Icube Strasbourg;
Nicolò BIZZARRI, MD
principal investigator · Fondazione Policlinico Universitario A. Gemelli, IRCCS, Rome Italy
Lise LECOINTRE, MD, PhD
principal investigator · University Hospitals of Starsbourg; Icube Strasbourg; IHU Strasbourg
Denis QUERLEU, MD, PhD
study chair · Fondazione Policlinico Universitario A. Gemelli, IRCCS, Rome Italy
Nicolas PADOY, PhD
study chair · IHU Strasbourg
Giovanni SCAMBIA, MD, PhD
study director · Fondazione Policlinico Universitario A. Gemelli, IRCCS, Rome Italy
Francesco FANFANI, MD, PhD
study chair · Fondazione Policlinico Universitario A. Gemelli, IRCCS, Rome Italy
Cherif AKLADIOS, MD, PhD
study chair · University Hospitals of Strasbourg
Pietro MASCAGNI, MD, PhD
study chair · Fondazione Policlinico Universitario A. Gemelli, IRCCS, Rome Italy
Valentina IACOBELLI, MD
study chair · Fondazione Policlinico Universitario A. Gemelli, IRCCS, Rome Italy
Andrea ROSATI, MD
study chair · Fondazione Policlinico Universitario A. Gemelli, IRCCS, Rome Italy

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion